了解双重挑战:在风湿性关节炎治疗中药物不良反应和坚持治疗
Aishwarya Nikose1, Swati Patil2,3, Neha Kadhe3
1Pharmacology and Therapeutics, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai, IND.
Cureus
|February 3, 2025
概括
使用疾病修饰性抗风湿药物 (DMARDs) 的患者经常出现胃肠道副作用,但保持高药物守. 甲索酸不耐受性很低,可能是由于叶酸的使用.
科学领域:
- 类风湿病学 类风湿病学
- 临床药理学 临床药理学
背景情况:
- 改变疾病的抗风湿药物 (DMARDs) 对于治疗类风湿性关节炎 (RA) 至关重要.
- 甲基是一种广泛使用的DMARD,但其疗效可能受到药物不良反应 (ADR) 和不良坚持的限制.
- 了解现实世界的ADRs和坚持对于优化RA治疗至关重要.
研究的目的:
- 为了调查在接受甲铁酸治疗的患者中发生的ADRs.
- 评估RA患者的药物坚持和甲状腺素不耐受性.
- 探索影响坚持和不容忍的因素.
主要方法:
- 一项对100名成人RA患者进行的横截面观察性研究.
- 通过患者报告和实验室测试记录了ADR.
- 使用风湿病学合规性问卷 (CQR5) 测量了药物坚持;不耐受性用甲醇不耐受性严重性得分 (MISS) 进行评估.
主要成果:
- 胃肠道副反应是最常见的 (76.53%),其次是血液学问题 (16.07%).
- 尽管有副作用,但观察到药物坚持度很高.
- 甲索酸不耐受性很低,可能与普遍的叶酸补充剂有关.
结论:
- 胃肠道的不良反应在接受甲托雷克萨特治疗的RA患者中很常见.
- 尽管有ADRs,但注意到对甲状腺素治疗的高度坚持.
- 需要对患者咨询和疾病知识等因素进行进一步的研究,以解释坚持水平.
相关概念视频
Drug Therapy
37
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
37
Pharmacovigilance
769
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
769
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Drug-Receptor Interactions
4.8K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.8K
Combined Effects of Drugs: Antagonism
8.2K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114


